Policybazaar - health-tech - unit - VisitHealth - techxmedia

Policybazaar subsidiary health-tech unit invests $7.5 M in Visit Health

Healthcare Industries

Policybazaar subsidiary health-tech unit Docprime Technologies invested $7.5 M in Visit Health, a telehealth and wellness platform.

Docprime has made its first investment in a complete telehealth and wellness platform. Visit Health, which has been around for five years, offers an integrated solution that allows businesses to provide their employees with access to recognized specialists while also assisting them in managing their healthcare needs. The technology enables businesses to improve their employees’ healthcare experiences while also lowering medical costs.

According to PB Fintech, the investment would help it improve its service capabilities in the health and wellness industry.

 “Our goal with this investment is to back Visit Health in their vision to build a strong Digital Health Ecosystem – with outstanding customer service and new ways to help customers navigate a healthcare system. We are proud to back Visit as they approach their next phase of growth,” said Yashish Dahiya, chairman and chief executive officer, PB Fintech.

Docprime, which was launched in August 2018 by Policybazaar’s parents, allows consumers to make appointments with doctors and diagnostic labs via its website. The site also serves as a middleman or facilitator for a variety of healthcare, wellness, and personal care products.

 “Visit is excited to have PB Fintech as a partner in our strategic vision to create a Digital Health Ecosystem. Our product offering is backed by Health insurers and the large cashless network stitched by us. With this investment, we plan to grow our platform and network capabilities and expand our teams across technology, sales, and network functions,” said Visit Health’s chief executive officer, Anurag Prasad, on the acquisition.

Visit Health previously secured $1.4 million in a seed round and is backed by Snapdeal founders Kunal Bahl and Rohit Bansal and Hetero Drugs Director Murali Krishna.


Leave a Reply

Your email address will not be published. Required fields are marked *